Skip to main content

First in vitro model for stable replication of archetypal BK polyomavirus in RPTEC and retinoids as potent candidates for BK-Polyomavirus treatment

Ref-Nr: TA-2016/03


Kurzfassung

Inventors from the Saarland University Medical Centre in Homburg established the first in vitro model for stable replication of archetypal BK polyomavirus. The invention allowed the scientists to find promising candidates for a specific treatment of BK polyomavirus infections.


Hintergrund

The BK polyomavirus (BKPyV) has pathogenic relevance especially in immunocompromised patients such as kidney and bone marrow transplant patients leading to nephropathy and hemorrhagic cystitis. No causal therapy has been established yet, particularly, because appropriate cell culture models for archetype virus replication are missing and therefore a starting point for potent and effective drug development does not exist.


Problemstellung

Drug research and development had to either rely on rearranged strains, or use alternative cells or cell lines that do not mirror “true-to-life” conditions of BKPyV infection, persistence and reactivation. So there is a desperate need for a replication system that imitates real life conditions and allows both further investigation of archetypal BKPyV life cycle as well as the development of antiviral drugs with higher efficacy and specificity, to improve current outcomes of BKPyV-mediated nephropathy and hemorrhagic cystitis


Lösung

The present technology provides, for the first time, an in vitro method for stable replication of wild type BK polyomavirus in cell culture. The technology allows propagation of the archetypal BKPyV in primary Renal Proximal Tubule Epithelial Cells (RPTEC) and is excellently suited for drug screening and identification of BK replication-inhibitors. Using this groundbreaking method the scientists were able to identify potent BK-Inhibitors presenting promising candidates for the specific treatment of BK polyomavirus infection. The detected inhibitors belong to the retinoid family. In particular the third-generation retinoid Bexarotene, already approved for treatment for cutaneous T cell lymphoma, and Fenretinide, a synthetic phenylretinamide analogue of retinol, were able to inhibit BK-replication and to reduce viral load efficiently without eliciting toxic effects.

 

 


Vorteile

- "true-to-life" conditions of BK polyomavirus infection, persistence and reactivation

- "true-to-life" drug screening


Anwendungsbereiche

- excellent applicability of said system for identifying BK polyomavirus inhibiting compounds

 

 


Service

We are looking for partners for further development and/or commercialization of the invention.


Universität des Saarlandes Wissens- und Technologietransfer GmbH

Dr. Melanie Hennchen
0681 302-6382
melanie.hennchen@uni-saarland.de
www.wut-uni-saarland.de
Adresse
Universität des Saarlandes Wissens- und Technologietransfer GmbH Starterzentrum | Gebäude A1 1
66123 Saarbrücken



Entwicklungsstand

Prototyp


Patentsituation

  • PCT anhängig

Stichworte

BK polyomavirus, Bexarotene, Fenretinide, infection

Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsstellenleiterin)

c/o PROvendis GmbH
Schloßstr. 11-15
D-45468 Mülheim an der Ruhr